Literature DB >> 16168039

Does psychological treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder?

Francis Creed1, Elspeth Guthrie, Joy Ratcliffe, Lakshmi Fernandes, Christine Rigby, Barbara Tomenson, Nicholas Read, David G Thompson.   

Abstract

OBJECTIVE: We have previously reported improved health-related quality of life in patients with severe irritable bowel syndrome (IBS) following psychological treatments. In this paper, we examine whether this improvement was associated with improvement in psychological symptoms and was confined to those patients who had concurrent psychiatric disorder.
METHOD: Two hundred and fifty-seven patients with severe IBS entering a psychological treatment trial were interviewed using the Schedules for Clinical Assessment in Neuropsychiatry. At entry to the trial and 15 months later, patients were also assessed using the Hamilton Depression Rating Scale, Symptom Cheecklist-90 (SCL-90) and Short Form-36 (SF36) physical component summary score as the main outcome measure. Partial correlation was used to compare changes in SF36 score and changes in psychological scores while controlling for possible confounders, treatment group and baseline scores. Multiple regression analysis was used to examine whether changes in psychological scores, changes in pain and a history of abuse could account for most of the variance of change in SF36 physical component score.
RESULTS: Of 257 patients with severe IBS, 107 (42%) had a depressive, panic or generalized anxiety disorder at trial entry. There were moderate but significant correlations (0.21-0.47) between change in the psychological scores and the change in SF36 physical component scores. The correlation coefficients were similar in the groups with and without psychiatric disorder. The superiority of psychotherapy and antidepressant groups over treatment as usual was similar in those with and without psychiatric disorder. Multiple regression found significant independent effects of change in depression, anxiety, somatization and abdominal pain but there was still variance explained by treatment group.
CONCLUSIONS: In severe IBS improvement in health-related quality of life following psychotherapy or antidepressants is correlated with, but not explained fully by reduction of psychological scores. A more complete understanding of how these treatments help patients with medically unexplained symptoms will enable us to refine them further.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168039     DOI: 10.1080/j.1440-1614.2005.01686.x

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  17 in total

Review 1.  How do SSRIs help patients with irritable bowel syndrome?

Authors:  F Creed
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

Review 2.  Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment.

Authors:  P Paré; Ronald Bridges; Malcolm C Champion; Subhas C Ganguli; James R Gray; E Jan Irvine; Victor Plourde; Pierre Poitras; Geoffrey K Turnbull; Paul Moayyedi; Nigel Flook; Stephen M Collins
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

Review 3.  Psychosocial determinants of irritable bowel syndrome.

Authors:  Teodora Surdea-Blaga; Adriana Băban; Dan L Dumitrascu
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

4.  Are child anxiety and somatization associated with pain in pain-related functional gastrointestinal disorders?

Authors:  Amy E Williams; Danita I Czyzewski; Mariella M Self; Robert J Shulman
Journal:  J Health Psychol       Date:  2013-10-22

5.  [Psychopharmacological treatment in patients with somatoform disorders and functional body syndromes].

Authors:  H P Kapfhammer
Journal:  Nervenarzt       Date:  2012-09       Impact factor: 1.214

6.  Somatization is associated with physical health-related quality of life independent of anxiety and depression in cancer, glaucoma and rheumatological disorders.

Authors:  Thomas Hyphantis; Barbara Tomenson; Vassiliki Paika; Augoustina Almyroudi; Chrisavgi Pappa; Niki Tsifetaki; Paraskevi V Voulgari; Alexandros A Drosos; Nicholas Pavlidis; Francis Creed
Journal:  Qual Life Res       Date:  2009-08-22       Impact factor: 4.147

Review 7.  Irritable bowel syndrome and chronic pelvic pain: a singular or two different clinical syndrome?

Authors:  Anna Matheis; Ute Martens; Johannes Kruse; Paul Enck
Journal:  World J Gastroenterol       Date:  2007-07-07       Impact factor: 5.742

8.  How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial.

Authors:  Jeffrey M Lackner; James Jaccard; Susan S Krasner; Leonard A Katz; Gregory D Gudleski; Edward B Blanchard
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

9.  Hysterical again: the gastrointestinal woman in medical discourse.

Authors:  Amy Vidali
Journal:  J Med Humanit       Date:  2013-03

10.  History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study.

Authors:  David M Marks; Changsu Han; Stan Krulewicz; Chi-Un Pae; Kathleen Peindl; Ashwin A Patkar; Prakash S Masand
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.